Floatz logo

Avelumab

Stage IVB Bladder Cancer AJCC v8

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Stage IVB Bladder Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Pembrolizumab
M.D. Anderson Cancer Center
Phase 1/2B
Relatlimab
M.D. Anderson Cancer Center
Phase 2CCC
Glycosylated Recombinant Human Interleukin-7
National Cancer Institute (NCI)
Phase 2CCC

View all 12 →

Same molecule, other indications

Avelumab is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
urothelial carcinomaDormant
B
Indicative ·
58 / 100
View asset →
bladder transitional cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →